Pulmovant is a Roivant-backed clinical-stage biotechnology company developing innovative therapies for patients suffering from pulmonary diseases. Pulmovant’s first program, mosliciguat is designed to provide an effective, once-daily, inhaled treatment option for patients with pulmonary hypertension (PH). Mosliciguat is
DCE Design & Construction Program Manager Atlanta, GA; CO - Denver Corp; Dallas, TX; NC - Charlotte Corp/South; OR - Portland Hillsboro 1 (HUB); US (Remote) Mission: Serve as the central point of control linking core